Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Colorectal Neoplasms 9Melanoma 5Glioblastoma 5Uterine Cervical Neoplasms 4Rectal Neoplasms 4Gliosarcoma 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Brenner Tumor 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Brain Neoplasms 3Uveal Melanoma 2Squamous Cell Carcinoma of Head and Neck 2Spinal Cord Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Medulloblastoma 2Lung Neoplasms 2Glioma 2Astrocytoma 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Urethral Neoplasms 1

Interventions

veliparib 1tipifarnib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Neoplasm × Disulfides × Clear all
NCT01749384 2017-10-12

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
12 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡